Soliris®

Understanding Soliris® 

Soliris® (eculizumab) is a monoclonal antibody used to treat rare and serious autoimmune disorders by blocking a part of the immune system known as the complement system. Specifically, Soliris® inhibits the C5 protein, preventing excessive immune attacks that can lead to severe inflammation and tissue damage. By reducing these harmful immune responses, Soliris® helps alleviate symptoms, prevent relapses, and improve quality of life in patients with these conditions.

How Soliris® Works:

• Inhibits the C5 complement protein to prevent immune overactivation.
• Reduces inflammation and protects red blood cells, nerves, and blood vessels in affected conditions.
• Prevents relapses and disease progression in autoimmune disorders.

FDA Approvals:

• Paroxysmal Nocturnal Hemoglobinuria (PNH): Approved in 2007
• Atypical Hemolytic Uremic Syndrome (aHUS): Approved in 2011
• Generalized Myasthenia Gravis (gMG): Approved in 2017
• Neuromyelitis Optica Spectrum Disorder (NMOSD): Approved in 2019

For more information, please visit the Soliris® patient website and speak with your healthcare provider to determine if Soliris® is the right treatment option for you.